Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003117434 | SCV003786144 | uncertain significance | not provided | 2022-06-04 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Ile545Aspfs*13) in the CERKL gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 14 amino acid(s) of the CERKL protein. This variant is present in population databases (rs773497189, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with CERKL-related conditions. ClinVar contains an entry for this variant (Variation ID: 522513). This variant disrupts a region of the CERKL protein in which other variant(s) (p.Ser551Cys) have been observed in individuals with CERKL-related conditions (PMID: 29555955). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Baylor Genetics | RCV000625656 | SCV005057406 | pathogenic | Retinitis pigmentosa 26 | 2023-11-29 | criteria provided, single submitter | clinical testing | |
Bioscientia Institut fuer Medizinische Diagnostik Gmb |
RCV000625656 | SCV000746159 | pathogenic | Retinitis pigmentosa 26 | 2017-10-11 | no assertion criteria provided | clinical testing |